Výsledky vyhledávání - "Brad A. Gouker"

TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin

Publikováno v: Cancer Discov

Lung squamous cell carcinoma (LSCC) is the second most prevalent type of lung cancer. Despite extensive genomic characterization, no targeted therapies are approved for the treatment of LSCC. Distal amplification of the 3q chromosome is the most freq

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ae718344269386e6b8941094caa7fb
https://doi.org/10.1158/2159-8290.cd-20-0797

Zobrazit plný text záznamu

The root causes of pharmacodynamic assay failure

Autor: Jiuping J. Ji, Alice P. Chen, Brad A. Gouker, Ralph E. Parchment, Shivaani Kummar, James H. Doroshow, Kristina M. Bigelow, Robert J. Kinders, Katherine V. Ferry-Galow, Scott M. Lawrence, Deborah Wilsker, Donna Butcher, Thomas D. Pfister, William H. Yutzy, Hala R. Makhlouf, Allison M. Marrero

Publikováno v: Seminars in Oncology. 43:484-491

Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or vari

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ccc4493db2f40c861156f5996ecb459
https://doi.org/10.1053/j.seminoncol.2016.06.006

Zobrazit plný text záznamu

Abstract 845: A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics

Autor: Tony Navas, Brad A. Gouker, Susan Holbeck, Apurva K. Srivastava, Angelena Millione, Suzanne Borgel, Alice P. Chen, Donna Butcher, James H. Doroshow, Robert J. Kinders, Shivaani Kumar, Ralph E. Parchment, Melinda G. Hollingshead, Donald P. Bottaro, John Carter

Publikováno v: Cancer Research. 77:845-845

Epithelial-mesenchymal transition (EMT) is a critical process implicated in metastasis. Despite extensive research, the clinical significance of EMT remains unclear, and a quantitative evaluation of this process in human tumors has yet to be demonstr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83c1f371a4907c31ea49924f3e498d50
https://doi.org/10.1158/1538-7445.am2017-845

Zobrazit plný text záznamu

Abstract LB-B18: Epithelial to mesenchymal transition in human tumor biopsies: Quantitative, histopathological proof of the existence of EMT in vivo by immunofluorescence microscopy

Autor: James H. Doroshow, Ralph E. Parchment, Scott M. Lawrence, Tony Navas, Sergio Y. Alcoser, Lindsay Dutko, Hala R. Makhlouf, Rodrigo F. Chuaqui, Donald P. Bottaro, Katherine V. Ferry-Galow, Donna Butcher, Brad A. Gouker, Robert J. Kinders, Melinda G. Hollingshead, Thomas D. Pfister, Shivaani Kummar, Alice P. Chen, Apurva K. Srivastava

Publikováno v: Molecular Cancer Therapeutics. 14:LB-B18

Epithelial-mesenchymal transition (EMT) is a dynamic process whereby epithelial cells acquire mesenchymal properties. Despite the clinical significance of the acquired mesenchymal properties for metastasis and drug resistance, histopathological evide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe80f6f6ebe93a29de919a14a1ecfe5c
https://doi.org/10.1158/1535-7163.targ-15-lb-b18

Zobrazit plný text záznamu

Abstract 5082: Impact of HGF knockin microenvironment on epithelial-mesenchymal transition and cancer stem cells in a non-small cell lung cancer xenograft model

Autor: Elinor Ng-Eaton, Tony Navas, Scott M. Lawrence, Apurva K. Srivastava, Young H. Lee, Robert J. Kinders, Donna Butcher, Brad A. Gouker, James H. Doroshow, Joseph E. Tomaszewski, Melinda G. Hollingshead, Thomas D. Pfister, Sergio Y. Alcoser, Donald P. Bottaro, Naoko Takebe, Suzanne Borgel, Ralph E. Parchment, Lindsay Dutko

Publikováno v: Cancer Research. 75:5082-5082

We previously reported the generation of rabbit monoclonal antibodies to twelve EMT (epithelial-to-mesenchymal transition) transcription factors and cancer stem cell (CSC) markers for the development of pharmacodynamic assays to inform clinical trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59dceb8ad0c8ee6c3dcde3c0b25a089b
https://doi.org/10.1158/1538-7445.am2015-5082

Zobrazit plný text záznamu

Abstract 5279: Establishing robust pharmacodynamic (PD) immunofluorescence assays of clinical biopsies at the National Cancer Institute: Optimized quality control procedures for the evaluation of DNA damage response and epithelial-mesenchymal transition (EMT) biomarkers

Autor: Katherine V. Ferry-Galow, Tony Navas, Scott M. Lawrence, Robert J. Kinders, Donna Butcher, Brad A. Gouker, Jiuping Ji, Joseph E. Tomaszewski, Hala R. Makhlouf, Ralph E. Parchment, William H. Yutzy, James H. Doroshow, Shivaani Kummar

Publikováno v: Cancer Research. 75:5279-5279

Robust PD assay results are valuable for informing decisions about continued preclinical and clinical development of new agents and for identifying effective combinations of targeted agents. The National Cancer Institute's Division of Cancer Treatmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fde3970f423361ad2e95268b51355b67
https://doi.org/10.1158/1538-7445.am2015-5279

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání